Unknown

Dataset Information

Mitochondrial estrogen receptors alter mitochondrial priming and response to endocrine therapy in breast cancer cells.


ABSTRACT: Breast cancer is the most common cancer with a high rate of mortality and morbidity among women worldwide. Estrogen receptor status is an important prognostic factor and endocrine therapy is the choice of first-line treatment in ER-positive breast cancer. However, most tumors develop resistance to endocrine therapy. Here we demonstrate that BH3 profiling technology, in particular, dynamic BH3 profiling can predict the response to endocrine therapy agents as well as the development of acquired resistance in breast cancer cells independent of estrogen receptor status. Immunofluorescence analysis and subcellular fractionation experiments revealed distinct ER-α and ER-β subcellular localization patterns in breast cancer cells, including mitochondrial localization of both receptor subtypes. shR

SUBMITTER: Karakas B 

PROVIDER: S-EPMC8298581 | biostudies-literature | 2021 Jul

REPOSITORIES: biostudies-literature